However, SARS-CoV-2 can evade antiviral responses by actively interfering with IFN production (7–17), and the serum of patients with mild and moderate COVID-19 has similar levels of type I and III IFNs compared with healthy patients (18). This evidence concerns the gene IFNA1 and COVID-19.